The LLS Children’s Initiative Latest News
The LLS Children’s Initiative Latest News
The LLS Children’s Initiative is a $100 million multi-year effort to take on children’s cancer through every facet of our mission: Research, Patient Education and Support and Policy and Advocacy.
The LLS Children’s Initiative includes: more pediatric research grants, a global precision medicine clinical trial, expanded free education and support services for children and families and driving policies and laws that break down barriers to care.
On this page you will find the latest updates on every aspect of the initiative.
- If you have questions or comments please contact missioncommunications@lls.org
- If you are interested in volunteering for The LLS Children’s Initiative please visit www.volunteerlls.org
PRA Health Sciences Joins The Leukemia & Lymphoma Society on Global Trial for Children with Acute Leukemia
The Leukemia & Lymphoma Society (LLS) and PRA Health Sciences (NASDAQ: PRAH) announced today a partnership to launch a first-of-its-kind global master clinical trial to develop new treatments for children with relapsed acute leukemia.
LLS Announced a Collaboration with the National Cancer Institute and Children’s Oncology Group on a Global Master Clinical Trial for Children with Acute Leukemia
The Leukemia & Lymphoma Society (LLS) announced today a collaboration with the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) to launch a global precision medicine clinical trial for children with acute leukemia.
Forming a Global Collaboration
As we put the essential pieces together to launch a major precision medicine clinical trial for children with acute leukemia – LLS PedAL - one of the most important aspects of this trial will be its global reach. This LLS-led trial, which will test targeted therapies in children with acute myeloid leukemia, and eventually other high-risk leukemias, will benefit not only children in the United States, but in several European countries, as well as the UK, Australia, New Zealand and Canada.
The LLS Children’s Initiative Makes Headlines
Recently, Gwen Nichols, MD, Chief Medical Officer at LLS, shared her perspectives with STAT News on the urgent need to bring the promise of precision medicine to children with cancer. “Children with cancer are not benefiting enough from the progress we are making,” writes Dr. Nichols.
Sailing in One Direction to End Childhood Cancer
LLS is leading the charge to fundamentally change how we treat and care for children with blood cancer. But we can’t do it alone. The audience for the Atlanta event was approximately 80 parents and advocates from foundations focused on children touched by blood cancer. They heard from a panel of doctors who have joined with LLS Chief Medical Officer Dr. Gwen Nichols to develop and implement a bold global LLS-led clinical trial to bring precision medicine to children with acute leukemia.
Supporting The Next Generation of Research
LLS is currently funding approximately 30 research projects specifically focused on childhood blood cancers. Further, LLS also supports grants that are relevant to adolescent and young adult cancer patients.
LLS PedAL: Precision Medicine for Children with Leukemia
As part of The LLS Children’s Initiative, LLS is working with a team of renowned pediatric oncologists to lay the groundwork for a global precision medicine master clinical trial to match children with relapsed acute leukemia to a targeted therapy based on the specific abnormalities driving their cancer.